{"id":"amg-073","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to an allosteric site on the calcium-sensing receptor, AMG 073 enhances the receptor's ability to detect circulating calcium levels, leading to decreased PTH production and secretion. This results in lower serum calcium and phosphorus levels in patients with secondary hyperparathyroidism. The drug is particularly useful in dialysis patients where conventional treatments are inadequate.","oneSentence":"AMG 073 is a calcimimetic agent that allosterically activates the calcium-sensing receptor on the parathyroid gland, increasing its sensitivity to extracellular calcium and thereby suppressing parathyroid hormone secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:27.196Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis"}]},"trialDetails":[{"nctId":"NCT06434961","phase":"PHASE3","title":"The Trial of SHR6508 in Secondary Hyperparathyroidism","status":"COMPLETED","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-06-14","conditions":"Secondary Hyperparathyroidism","enrollment":498},{"nctId":"NCT07122401","phase":"PHASE3","title":"Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism","status":"RECRUITING","sponsor":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","startDate":"2025-09-30","conditions":"Secondary Hyperparathyroidism, Chronic Kidney Disease","enrollment":424},{"nctId":"NCT03994172","phase":"PHASE4","title":"Novel Combination Therapy for Osteoporosis in Men","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2019-07-01","conditions":"Male Osteoporosis","enrollment":40},{"nctId":"NCT07049718","phase":"NA","title":"Effect of Whole-body Vibration Training in Patients With Renal Dialysis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-02-15","conditions":"Renal Dialysis","enrollment":60},{"nctId":"NCT07007338","phase":"","title":"Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving Cinacalcet","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-09","conditions":"Children Over 3 Undergoing Dialysis With Secondary Hyperparathyroidism","enrollment":20},{"nctId":"NCT06288451","phase":"PHASE2","title":"DePTH: De-emphasize PTH","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-03-11","conditions":"Kidney Failure, Chronic, Chronic Kidney Disease-Mineral and Bone Disorder","enrollment":90},{"nctId":"NCT00415584","phase":"PHASE1, PHASE2","title":"Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2007-02-09","conditions":"Secondary Hyperparathyroidism, Hypercalcemia","enrollment":4},{"nctId":"NCT02133404","phase":"PHASE2","title":"A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-03-14","conditions":"Secondary Hyperparathyroidism","enrollment":62},{"nctId":"NCT02227264","phase":"NA","title":"Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2014-06","conditions":"Primary Hyperparathyroidism","enrollment":110},{"nctId":"NCT03123406","phase":"PHASE4","title":"Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT","status":"COMPLETED","sponsor":"Kyowa Kirin China Pharmaceutical Co., Ltd.","startDate":"2017-04-19","conditions":"Hyperparathyroidism; Secondary, Renal","enrollment":750},{"nctId":"NCT05926570","phase":"PHASE4","title":"Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-08-05","conditions":"Drug Effect","enrollment":35},{"nctId":"NCT05663411","phase":"PHASE2","title":"A Study of SHR6508 in Secondary Hyperparathyroidism","status":"UNKNOWN","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2023-02-24","conditions":"Secondary Hyperparathyroidism","enrollment":75},{"nctId":"NCT02525796","phase":"PHASE2, PHASE3","title":"Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-01","conditions":"Primary Hyperparathyroidism","enrollment":69},{"nctId":"NCT02440581","phase":"NA","title":"Renal Osteodystrophy: An Individual Management Approach","status":"COMPLETED","sponsor":"Hartmut Malluche, MD","startDate":"2015-07-01","conditions":"Kidney Failure, Chronic","enrollment":141},{"nctId":"NCT00345839","phase":"PHASE3","title":"E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-08-22","conditions":"Secondary Hyperparathyroidism, Chronic Kidney Disease","enrollment":3883},{"nctId":"NCT03822507","phase":"PHASE3","title":"Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2019-04-09","conditions":"Secondary Hyperparathyroidism","enrollment":404},{"nctId":"NCT01447368","phase":"PHASE4","title":"Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2010-05-10","conditions":"Kidney Failure, Secondary Hyperparathyroidism, Vascular Diseases","enrollment":67},{"nctId":"NCT03027557","phase":"PHASE3","title":"Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.","status":"COMPLETED","sponsor":"Peter Vestergaard","startDate":"2017-03-01","conditions":"Primary Hyperparathyroidism, Parathyroid Adenoma, Parathyroid Hyperplasia","enrollment":46},{"nctId":"NCT03299244","phase":"PHASE3","title":"Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-05-15","conditions":"Secondary Hyperparathyroidism, Chronic Kidney Disease","enrollment":637},{"nctId":"NCT01011114","phase":"NA","title":"Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2009-11","conditions":"Hypophosphatemia, Renal Transplant","enrollment":40},{"nctId":"NCT00195936","phase":"PHASE1","title":"Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2005-06","conditions":"Hypophosphatemic Rickets, X-Linked Dominant","enrollment":8},{"nctId":"NCT00844740","phase":"NA","title":"Calcimimetics in Hypophosphatemic Rickets","status":"WITHDRAWN","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2009-03-01","conditions":"Familial Hypophosphatemic Rickets","enrollment":""},{"nctId":"NCT04637360","phase":"NA","title":"Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment","status":"COMPLETED","sponsor":"Min-Sheng General Hospital","startDate":"2018-01-01","conditions":"Hyperparathyroidism; Secondary, Renal","enrollment":40},{"nctId":"NCT01277510","phase":"PHASE3","title":"Pediatric Chronic Kidney Disease Safety and Efficacy","status":"TERMINATED","sponsor":"Amgen","startDate":"2011-06-28","conditions":"Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary","enrollment":43},{"nctId":"NCT02138838","phase":"PHASE3","title":"Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-11-07","conditions":"Chronic Kidney Disease, Secondary Hyperparathyroidism","enrollment":55},{"nctId":"NCT02341417","phase":"PHASE3","title":"Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-06-10","conditions":"Secondary Hyperparathyroidism, Chronic Kidney Disease","enrollment":28},{"nctId":"NCT01439867","phase":"PHASE2","title":"Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism","status":"TERMINATED","sponsor":"Amgen","startDate":"2012-06-22","conditions":"Chronic Kidney Disease, Hyperparathyroidism, Secondary","enrollment":18},{"nctId":"NCT01290029","phase":"PHASE1","title":"Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-01-25","conditions":"Chronic Kidney Disease, Hyperparathyroidism, Secondary, Secondary Hyperparathyroidism","enrollment":14},{"nctId":"NCT01519037","phase":"NA","title":"Interaction Between a Calcimimetic Agent and the Renin Angiotensine Aldosterone System","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2012-01","conditions":"Relationship Between Calcimimetic and the RAAS","enrollment":18},{"nctId":"NCT04126954","phase":"","title":"Study on the Use of Cinacalcet in Phosphocalcic Context.","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2020-01","conditions":"Hyperparathyroidism, Secondary, Hyperparathyroidism, Primary","enrollment":25},{"nctId":"NCT01896232","phase":"PHASE3","title":"Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-08-13","conditions":"Secondary Hyperparathyroidism, Chronic Kidney Disease","enrollment":683},{"nctId":"NCT03776058","phase":"PHASE2","title":"Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)","status":"COMPLETED","sponsor":"Amgen","startDate":"2000-06-15","conditions":"Primary Hyperparathyroidism","enrollment":10},{"nctId":"NCT03774771","phase":"PHASE2","title":"Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism","status":"COMPLETED","sponsor":"Amgen","startDate":"1998-09-29","conditions":"Primary Hyperparathyroidism","enrollment":48},{"nctId":"NCT00975221","phase":"PHASE3","title":"Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-03-10","conditions":"Hyperparathyroidism, Primary, Hypercalcemia","enrollment":67},{"nctId":"NCT00975000","phase":"PHASE3","title":"Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-12-03","conditions":"Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure","enrollment":114},{"nctId":"NCT00803712","phase":"PHASE4","title":"20070360 Incident Dialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-02-01","conditions":"Chronic Kidney Disease, Secondary Hyperparathyroidism","enrollment":313},{"nctId":"NCT01932970","phase":"PHASE3","title":"Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-08-12","conditions":"Hyperparathyroidism, Secondary","enrollment":158},{"nctId":"NCT01181531","phase":"PHASE4","title":"Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-10-01","conditions":"Hyperparathyroidism, Secondary","enrollment":312},{"nctId":"NCT00928408","phase":"","title":"PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-10","conditions":"Hyperparathyroidism, Primary","enrollment":305},{"nctId":"NCT03603444","phase":"","title":"Reliability of Serum Calcium to Phosphorus (Ca/P) Ratio as an Accurate and Inexpensive Tool to Define Disorders of Ca-P Metabolism","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2011-01-01","conditions":"Phosphorus and Calcium Disorders","enrollment":606},{"nctId":"NCT02216656","phase":"PHASE2","title":"Phase 2 Study of KHK7580","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2014-07","conditions":"Secondary Hyperparathyroidism","enrollment":201},{"nctId":"NCT01054079","phase":"PHASE2","title":"Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2011-09","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer","enrollment":20},{"nctId":"NCT01748812","phase":"PHASE1","title":"Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)","status":"TERMINATED","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2012-11-16","conditions":"Osteomalacia","enrollment":1},{"nctId":"NCT00325104","phase":"PHASE3","title":"Cinacalcet to Treat Familial Primary Hyperparathyroidism","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2006-05-09","conditions":"Hypercalcemia, Familial Primary Hyperparathyroidism","enrollment":25},{"nctId":"NCT02549391","phase":"PHASE2, PHASE3","title":"Phase 3 Study of KHK7580","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2015-09","conditions":"Secondary Hyperparathyroidism","enrollment":634},{"nctId":"NCT01460030","phase":"PHASE3","title":"An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2011-11","conditions":"Parathyroid Carcinoma, Hypercalcemia, Primary Hyperparathyroidism","enrollment":""},{"nctId":"NCT01100723","phase":"PHASE4","title":"Trial to Optimize Mineral Outcomes in Dialysis Patients","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-03","conditions":"Secondary Hyperparathyroidism, Chronic Kidney Disease","enrollment":92},{"nctId":"NCT01011699","phase":"PHASE3","title":"Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2010-01","conditions":"Chronic Renal Failure, Hemodialysis","enrollment":176},{"nctId":"NCT01573520","phase":"PHASE4","title":"Treatment Adhesion in Dialysis Patients Treated With Cinacalcet","status":"COMPLETED","sponsor":"Michel Burnier","startDate":"2010-01","conditions":"Hyperparathyroidism, Chronic Kidney Disease","enrollment":50},{"nctId":"NCT02273570","phase":"NA","title":"Optimal Anemia Treatment in End Stage Renal Disease (ERSD)","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Sant'Anna","startDate":"2015-03","conditions":"Hyperparathyroidism, Secondary","enrollment":50},{"nctId":"NCT01178450","phase":"PHASE4","title":"Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation","status":"COMPLETED","sponsor":"Josep M Cruzado","startDate":"2010-01","conditions":"Secondary Hyperparathyroidism","enrollment":30},{"nctId":"NCT02417389","phase":"PHASE4","title":"Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2008-05","conditions":"Hyperparathyroidism, Primary, Osteoporosis","enrollment":22},{"nctId":"NCT02338934","phase":"PHASE4","title":"Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients","status":"UNKNOWN","sponsor":"Penang Hospital, Malaysia","startDate":"2015-01","conditions":"Secondary Hyperparathyroidism","enrollment":30},{"nctId":"NCT00446329","phase":"PHASE4","title":"Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis","status":"TERMINATED","sponsor":"Papageorgiou General Hospital","startDate":"2006-07","conditions":"Secondary Hyperparathyroidism","enrollment":15},{"nctId":"NCT00379899","phase":"PHASE4","title":"ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-09","conditions":"Chronic Kidney Disease, End Stage Renal Disease, Coronary Artery Calcification","enrollment":360},{"nctId":"NCT00261950","phase":"PHASE2","title":"Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-05","conditions":"Secondary Hyperparathyroidism","enrollment":110},{"nctId":"NCT01250405","phase":"PHASE4","title":"Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients","status":"COMPLETED","sponsor":"Laval University","startDate":"2012-05","conditions":"Chronic Kidney Disease","enrollment":23},{"nctId":"NCT00135304","phase":"PHASE4","title":"ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-08","conditions":"Secondary Hyperparathyroidism","enrollment":170},{"nctId":"NCT01143987","phase":"PHASE4","title":"Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2010-06","conditions":"Hyperparathyroidism, Arterial Stiffness","enrollment":44},{"nctId":"NCT01103206","phase":"PHASE4","title":"Evaluation of a Cincalcet Suppression Test","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2010-04","conditions":"Parathyroid Hormone Suppression Test With Cinacalcet","enrollment":36},{"nctId":"NCT00117052","phase":"PHASE3","title":"SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-09","conditions":"Secondary Hyperparathyroidism, End Stage Renal Disease","enrollment":673},{"nctId":"NCT00113958","phase":"PHASE2","title":"Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"End Stage Renal Disease","enrollment":""},{"nctId":"NCT00042432","phase":"PHASE2","title":"Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-06","conditions":"Secondary Hyperparathyroidism, Chronic Renal Insufficiency","enrollment":54},{"nctId":"NCT00113945","phase":"PHASE2","title":"Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-07","conditions":"End Stage Renal Disease","enrollment":360},{"nctId":"NCT00936650","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)","status":"COMPLETED","sponsor":"Amgen","startDate":"1999-11","conditions":"Hyperparathyroidism, Primary","enrollment":78},{"nctId":"NCT00042653","phase":"PHASE3","title":"A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-05","conditions":"Secondary Hyperparathyroidism, End Stage Renal Disease","enrollment":380},{"nctId":"NCT00037518","phase":"PHASE4","title":"A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2001-04","conditions":"Hyperparathyroidism, Parathyroid Neoplasms","enrollment":46},{"nctId":"NCT00037635","phase":"PHASE3","title":"A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2001-12","conditions":"Secondary Hyperparathyroidism, End Stage Renal Disease","enrollment":400},{"nctId":"NCT00936988","phase":"PHASE2","title":"A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism","status":"COMPLETED","sponsor":"Amgen","startDate":"2000-11","conditions":"Hyperparathyroidism, Primary","enrollment":45},{"nctId":"NCT00094484","phase":"PHASE3","title":"Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-10","conditions":"Kidney Disease, Chronic Kidney Disease","enrollment":400},{"nctId":"NCT00527085","phase":"PHASE2","title":"12-month Study of AMG 073 in Renal Osteodystrophy","status":"COMPLETED","sponsor":"Amgen","startDate":"2001-10","conditions":"Renal Osteodystrophy","enrollment":45},{"nctId":"NCT00431496","phase":"PHASE4","title":"A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-09","conditions":"Anemia, Secondary Hyperparathyroidism","enrollment":71},{"nctId":"NCT01599962","phase":"PHASE2","title":"Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects","status":"COMPLETED","sponsor":"Prof. Dominique de Quervain, MD","startDate":"2012-03","conditions":"Memory Functions","enrollment":40},{"nctId":"NCT00977080","phase":"PHASE4","title":"Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-11","conditions":"Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis","enrollment":272},{"nctId":"NCT01101113","phase":"PHASE4","title":"Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2010-09","conditions":"Secondary Hyperparathyroidism","enrollment":66},{"nctId":"NCT00656032","phase":"PHASE2","title":"Vitamin D, Insulin Resistance and Inflammation in ESRD","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2008-04","conditions":"End Stage Renal Disease","enrollment":12},{"nctId":"NCT01479088","phase":"PHASE2, PHASE3","title":"Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)","status":"UNKNOWN","sponsor":"ENRICO VERRINA","startDate":"2010-03","conditions":"Secondary Hyperparathyroidism","enrollment":30},{"nctId":"NCT00110890","phase":"PHASE4","title":"A Research Study for Patients With End-Stage Renal Disease (ESRD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-05","conditions":"End Stage Renal Disease","enrollment":552},{"nctId":"NCT00110656","phase":"","title":"Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-03","conditions":"Kidney Transplantation","enrollment":38},{"nctId":"NCT00110929","phase":"PHASE2","title":"Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-11","conditions":"End Stage Renal Disease","enrollment":850},{"nctId":"NCT00132431","phase":"PHASE4","title":"START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-07","conditions":"Kidney Disease, Secondary Hyperparathyroidism, Chronic Kidney Disease","enrollment":300},{"nctId":"NCT00527267","phase":"PHASE3","title":"Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-02","conditions":"Hyperparathyroidism","enrollment":320},{"nctId":"NCT00395902","phase":"","title":"Post Transplant Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-08","conditions":"Kidney Tansplant, Secondary Hyperparathyroidism, Hyperparathyroidism","enrollment":50},{"nctId":"NCT00189501","phase":"","title":"A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-12","conditions":"Nephrology","enrollment":1000},{"nctId":"NCT00336739","phase":"NA","title":"The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects","status":"COMPLETED","sponsor":"Tufts University","startDate":"2006-04","conditions":"Healthy","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"AMG 073","genericName":"AMG 073","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMG 073 is a calcimimetic agent that allosterically activates the calcium-sensing receptor on the parathyroid gland, increasing its sensitivity to extracellular calcium and thereby suppressing parathyroid hormone secretion. Used for Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}